Cargando…

Modeling Disease Trajectories for Castration-resistant Prostate Cancer Using Nationwide Population-based Data

BACKGROUND: Little is known about disease trajectories for men with castration-resistant prostate cancer (CRPC). OBJECTIVE: To create a state transition model that estimates time spent in the CRPC state and its outcomes. DESIGN, SETTING, AND PARTICIPANTS: The model was generated using population-bas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ventimiglia, Eugenio, Bill-Axelson, Anna, Adolfsson, Jan, Aly, Markus, Eklund, Martin, Westerberg, Marcus, Stattin, Pär, Garmo, Hans
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Prostate Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520495/ https://www.ncbi.nlm.nih.gov/pubmed/36185582 http://dx.doi.org/10.1016/j.euros.2022.07.010

Ejemplares similares

Changes in Characteristics of Men with Lethal Prostate Cancer During the Past 25 Years: Description of Population-based Deaths
por: Lycken, Magdalena, et al.
Publicado: (2022)

Satisfaction with Nurse-led Follow-up in Prostate Cancer Patients—A Nationwide Population-based Study
por: Bergengren, Oskar, et al.
Publicado: (2022)

Variations in the Uptake of Active Surveillance for Prostate Cancer and Its Impact on Outcomes
por: Ahlberg, Mats S., et al.
Publicado: (2023)

Mortality in men with castration‐resistant prostate cancer—A long‐term follow‐up of a population‐based real‐world cohort
por: Khoshkar, Yashar, et al.
Publicado: (2021)

Long-term Outcomes Among Men Undergoing Active Surveillance for Prostate Cancer in Sweden
por: Ventimiglia, Eugenio, et al.
Publicado: (2022)

Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms
por: Nordström, Tobias, et al.
Publicado: (2021)

A drug comorbidity index to predict mortality in men with castration resistant prostate cancer
por: Fallara, Giuseppe, et al.
Publicado: (2021)

The STHLM3-model, Risk-based Prostate Cancer Testing Identifies Men at High Risk Without Inducing Negative Psychosocial Effects
por: Koitsalu, Marie, et al.
Publicado: (2021)

Variation in Prostate-Specific Antigen Testing Rates and Prostate Cancer Treatments and Outcomes in a National 20-Year Cohort
por: Bergengren, Oskar, et al.
Publicado: (2021)

Digital Rectal Examination in Stockholm3 Biomarker-based Prostate Cancer Screening
por: Andersson, Joel, et al.
Publicado: (2022)

PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
por: Ferraldeschi, Roberta, et al.
Publicado: (2015)

Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry
por: Bjartell, Anders, et al.
Publicado: (2022)

Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial
por: Izumi, Kouji, et al.
Publicado: (2022)

Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)
por: Coelingh Bennink, Herjan J.T., et al.
Publicado: (2021)

Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population‐based study
por: Tomic, Katarina, et al.
Publicado: (2018)

Population‐based study of long‐term functional outcomes after prostate cancer treatment
por: Carlsson, Sigrid, et al.
Publicado: (2015)

Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate Cancer
por: Guldvik, Ingrid Jenny, et al.
Publicado: (2022)

External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort
por: Chandra Engel, Jan, et al.
Publicado: (2022)

A Prospective Study of the Relationship Between Clinical Outcomes After Enzalutamide and Serum Androgen Levels Measured via Liquid Chromatography-tandem Mass Spectrometry in Patients with Castration-resistant Prostate Cancer
por: Miyazawa, Yoshiyuki, et al.
Publicado: (2021)

Use of 5α-reductase inhibitors for lower urinary tract symptoms and risk of prostate cancer in Swedish men: nationwide, population based case-control study
por: Robinson, David, et al.
Publicado: (2013)

A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study
por: Waldén, Mauritz, et al.
Publicado: (2022)

Feasibility and Optimal Time Point of [(68)Ga]Gallium-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography Imaging in Patients Undergoing Cytoreductive Surgery After Systemic Therapy for Primary Oligometastatic Prostate Cancer: Implications for Patient Selection and Extent of Surgery
por: Huebner, Nicolai, et al.
Publicado: (2022)

Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study
por: Thomsen, Frederik B., et al.
Publicado: (2020)

Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer
por: Crawley, Danielle, et al.
Publicado: (2016)

Reducing Biopsies and Magnetic Resonance Imaging Scans During the Diagnostic Pathway of Prostate Cancer: Applying the Rotterdam Prostate Cancer Risk Calculator to the PRECISION Trial Data
por: Remmers, Sebastiaan, et al.
Publicado: (2021)

Clinical Application of the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Score for Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer
por: Aerts, Jan, et al.
Publicado: (2023)

Magnetic Resonance Imaging–targeted Prostate Biopsy Compared with Systematic Prostate Biopsy in Biopsy-naïve Patients with Suspected Prostate Cancer
por: Alkema, Nicolette G., et al.
Publicado: (2022)

Multiparametric Magnetic Resonance Imaging of the Prostate and Prostate-specific Membrane Positron Emission Tomography Prior to Prostate Biopsy (MP4 Study)
por: Woo, Henry H., et al.
Publicado: (2022)

Defining Prostatic Vascular Pedicle Recurrence and the Anatomy of Local Recurrence of Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography
por: Dundee, Philip, et al.
Publicado: (2022)

Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden
por: Van Hemelrijck, Mieke, et al.
Publicado: (2010)

Profiling of Skeletal Muscle and Adipose Tissue Depots in Men with Advanced Prostate Cancer Receiving Different Forms of Androgen Deprivation Therapy
por: Blow, Tahj A., et al.
Publicado: (2023)

Prostate Cancer Risk Inflation as a Consequence of Image-targeted Biopsy of the Prostate: A Computer Simulation Study
por: Robertson, Nicola L., et al.
Publicado: (2014)

Clinical Utility of Negative Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer and Clinically Significant Prostate Cancer
por: Wagaskar, Vinayak G., et al.
Publicado: (2021)

Prostate Cancer Tumor Volume and Genomic Risk
por: Ramaswamy, Ashwin, et al.
Publicado: (2023)

Germline ATM Mutations Detected by Somatic DNA Sequencing in Lethal Prostate Cancer
por: Grochot, Rafael, et al.
Publicado: (2023)

Which Prostate Cancers are Undetected by Multiparametric Magnetic Resonance Imaging in Men with Previous Prostate Biopsy? An Analysis from the PICTURE Study
por: Norris, Joseph M., et al.
Publicado: (2021)

A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy
por: Kelly, Brian D., et al.
Publicado: (2023)

The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator
por: Parekh, Sneha, et al.
Publicado: (2022)

Comparison of Survival Outcomes and Risk Factors Between Ductal Carcinoma of the Prostate and Acinar Adenocarcinoma of the Prostate: A Population-based Propensity Score–matching Study
por: Wei, Yongbao, et al.
Publicado: (2022)

Accuracy of Prostate Magnetic Resonance Imaging: Reader Experience Matters
por: Kang, Hyunseon C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6s7djb0t0189idh5uiclck28n5